Last reviewed · How we verify
IFN beta(48 weeks)
Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.
Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity. Used for Multiple sclerosis (relapsing-remitting or secondary progressive forms).
At a glance
| Generic name | IFN beta(48 weeks) |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Interferon |
| Target | Interferon-alpha/beta receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IFN beta is a type I interferon that binds to the interferon-alpha/beta receptor (IFNAR) on cell surfaces, triggering JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, increased MHC expression, and modulation of pro-inflammatory cytokine production. The 48-week dosing regimen suggests chronic immunomodulation for a chronic disease indication.
Approved indications
- Multiple sclerosis (relapsing-remitting or secondary progressive forms)
Common side effects
- Flu-like symptoms (fever, chills, myalgia)
- Injection site reactions
- Headache
- Fatigue
- Elevated liver enzymes
- Leukopenia
- Depression/mood changes
Key clinical trials
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis (PHASE2, PHASE3)
- A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (PHASE2)
- Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (PHASE3)
- Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (PHASE3)
- Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (PHASE2)
- A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (PHASE4)
- REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |